MOR Overview
Upcoming Projects (MOR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MOR)
-
Discussing the standard of care for Myelofibrosis and the potential use of MorphoSys' BET inhibitor, pelabresib
Ticker: MOR
Executed On: Dec 14, 2023 at 04:30 PM EST -
Discussing Morphosys' pelabresib in myelofibrosis with a clinical trialist in advance of the upcoming Phase 3 readout anticipated in Q4 2023
Ticker: MOR
Executed On: Oct 30, 2023 at 11:00 AM EDT -
A Second Look: Examining Morphosys' pelabresib in anticipation of the phase 3 MANIFEST trial results and other bromodomain and extra-terminal (BET) inhibitors being developed for myelofibrosis.
Ticker: MOR
Executed On: Oct 17, 2023 at 04:30 PM EDT -
Examining Morphosys' pelabresib in anticipation of the phase 3 MANIFEST trial results and other bromodomain and extra-terminal (BET) inhibitors being developed for myelofibrosis.
Ticker: MOR
Executed On: Oct 13, 2023 at 01:00 PM EDT
Upcoming & Overdue Catalysts (MOR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (MOR)
-
Don’t see a strategic initiative related to the company you care about? Create your own!